Are you staying up Wednesday night to listen to GSK's webcast live?
It will be interesting to see just how much demand they have backed up for Relenza. Increasing production to 190m treatments per annum is massive for Biota. If you think about it though the western population is around 1bn, so is 190m/annum really enough?
I can't even imagine what the stock price will do if GSK can confirm orders of 100m+ treatment packs of relenza. Analyst re-ratings will surely start... the perfect storm is upon us!
BTA Price at posting:
$1.61 Sentiment: Buy Disclosure: Held
